Astellas Pharma Global Development, Inc.

CONTACT

Lead Sponsor

Astellas Pharma Global Development, Inc.

Age

All ages

Sex

ALL

Healthy Volunteers

No

•Patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in 1 or both eyes
•Patient with a decision to treat with intravitreal avacincaptad pegol (ACP) prior to enrollment
•Patient willingness to complete the patient reported outcome (PRO).

•* Active ocular or peri-ocular infection in either eye
•* Active, suspected intraocular inflammation in either eye at enrollment/baseline visit
•* Hypersensitive to ACP or to any ingredient in the formulation
•Patients currently participating in an investigational program with interventions outside of routine clinical practice.
•Patients who have received ACP in the study eye. Note: Patients who have received or are receiving ACP in the fellow eye are eligible to be included in the study.
•Patients who have received any intravitreal complement inhibitor other than ACP in either eye. Note: Patients who have received an intravitreal complement inhibitor other than ACP in either eye and have completed the 90-day washout period are eligible to be included in the study.